title: Ovulation induction in polycystic ovary syndrome: No. 242, May 2010.
abstract: OBJECTIVE
  To review current non-pharmacologic and pharmacologic options for ovulation induction in women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  This guideline reviews the evidence for the various options for ovulation induction in PCOS.
  
  
  RESULTS
  Ovulation, pregnancy and live birth rates, risks, and side effects are the outcomes of interest.
  
  
  METHODS
  Published literature was retrieved through searches of Medline using appropriate controlled vocabulary and key words. Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. Grey (unpublished) literature was identified through searching the websites of health technology assessment and of health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.
  
  
  METHODS
  The evidence gathered was reviewed and evaluated by the Reproductive Endocrinology and Infertility Committee of the Society of Obstetricians and Gynaecologists of Canada. The quality of evidence was quantified using the Canadian Task Force on Preventive Health Care.
  
  
  RESULTS
  Benefits include weight reduction and improvements in ovulation, pregnancy, and live birth rates. Potential harms include medication side effects and multiple pregnancies.
  
  
  RESULTS
  These guidelines have been reviewed and approved by the Reproductive Endocrinology and Infertility Committee of the SOGC.
authors.forename: Tannys D R
authors.initials: TD
authors.lastname: Vause
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Cheung
authors.forename: Sony
authors.initials: S
authors.lastname: Sierra
authors.forename: Paul
authors.initials: P
authors.lastname: Claman
authors.forename: James
authors.initials: J
authors.lastname: Graham
authors.forename: Jo-Anne
authors.initials: JA
authors.lastname: Guillemin
authors.forename: Louise
authors.initials: L
authors.lastname: Lapensée
authors.forename: Sabrina
authors.initials: S
authors.lastname: Steward
authors.forename: Benjamin Chee-Man
authors.initials: BC
authors.lastname: Wong
mesh_terms: D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D002996:Clomiphene / Q000627:therapeutic use*; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005307:Fertilization in Vitro; D006062:Gonadotropins / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007247:Infertility, Female / Q000188:drug therapy* / Q000601:surgery; D008687:Metformin / Q000627:therapeutic use*; D010053:Ovary / Q000601:surgery; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D015431:Weight Loss
chemical_list: D047072:Aromatase Inhibitors; D005300:Fertility Agents, Female; D006062:Gonadotropins; D007004:Hypoglycemic Agents; D002996:Clomiphene; D008687:Metformin